MedTrace Logo

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

NCT01939691 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-01-13

No results posted yet for this study

Summary

Macular edema is a condition in which there is swelling in the macula, the part of the retina that gives you your best vision. This swelling can cause your vision to decline. When diagnosed early and treated, you vision usually can be preserved. However, if the swelling goes untreated for a long time, it can cause permanent vision loss.

We think that the three eye drop regimens in this study, difluprednate, difluprednate plus nepafenac, and prednisolone acetate plus nepafenac, might be effective in treating uveitic macular edema. Patients who enter this study are randomized to one of the three regimens and followed for 24 weeks.

Conditions

  • Uveitis
  • Macular Edema

Interventions

DRUG

Difluprednate

Difluprednate 0.05% - corticosteroid eyedrop

DRUG

Nepafenac

Nepafenac 0.1% - NSAID eyedrop

DRUG

Prednisolone acetate

prednisolone acetate 1% - corticosteroid eyedrop

Sponsors & Collaborators

Principal Investigators

  • Nisha Acharya, MD MS · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-12
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939691 on ClinicalTrials.gov